studies were assessed by two independent reviewers before being potentially discarded, with the quality of papers assessed using a modified Jadad scale. The outcome measures included blood levels of glycated haemoglobin, episodes of hypoglycaemia, adverse effects and the reduction of microvascular and macrovascular end-organ complications of T1DM. Results Out of 803 studies found in the selected databases, only eight trials met the inclusion criteria. Most of the studies were of poor methodological quality or had a high risk of bias, with a mean score of 2.125 on the Jadad scale. No study could be classified as double-blind, and only one study documented the increased efficacy of insulin glargine in relation to both glycaemic control and hypoglycaemic episodes. Typically, there was no significant difference between insulin glargine and NPH insulins. Conclusions This systematic review showed no therapeutic benefit of insulin glargine over other insulin formulations studied when analysing together glycaemic control and the frequency and severity of hypoglycaemia. We therefore recommend to the State Authority to delist insulin glargine or renegotiate a price reduction with the manufacturer. This systematic review provides support for this decision as well as documentation to combat potential law suits if discussions are unsatisfactory.
Key Points for Decision Makers
• The costs of insulin glargine have been growing appreciably in the State of Minas Gerais in Brazil in recent years. This has been driven by an increasing number of successful law suits and substantial price differential between long-acting insulin analogues and other insulin formulations.
• A thorough systematic review would provide a rationale for whether to maintain insulin glargine on the list of the Public Health System (SUS) or delist it. In addition, it would provide potential arguments to defend against future law suits if pertinent.
• The review showed no added clinical benefit with insulin glargine over other insulin formulations, confirming the findings from other reviews.
• This review provides a basis for the State Government to seek either to delist insulin glargine or to negotiate a price reduction similar to other countries.
Introduction
There is increasing scrutiny on pharmaceutical expenditure among countries, driven by expenditure rising by more than 50 % in real terms between 2000 and 2009 among Organisation for Economic Co-operation and Development (OECD) countries [1] [2] [3] [4] [5] [6] . This has been driven by well known factors, including ageing populations, rising patient expectations and the continued launch of new premiumpriced drugs [7] . As a result, there will be continued growth in pharmaceutical expenditure unless there are further reforms to address this. Ongoing initiatives among countries to moderate growth rates in pharmaceutical expenditure include processes to robustly assess the value of new drugs against existing standards and to link this to reimbursed prices, encourage the prescribing of low-cost alternatives when care is not compromised, and disinvest in products that are seen to no longer provide value [1] [2] [3] [4] [5] [6] . An example of the latter is Sweden, which re-assessed the value of nearly 2,000 pharmaceuticals across a number of disease areas. These included drugs to treat migraine, excessive stomach acid, respiratory diseases, hypertension, depression and hyperlipidaemia [3, 5, [8] [9] [10] [11] . Following the review of respiratory diseases, cough medicines were delisted, as the reimbursement agency (the Dental and Pharmaceutical Benefits Agency [TLV]) believed it was unreasonable to reimburse those medicines with only limited efficacy and for short-term conditions with only relatively minor discomfort. Four asthma treatments were delisted from October 2007, including theophyllines for maintenance treatment as they were considered not cost effective against newer treatments [3, 5] . Prescribing restrictions have also been introduced for some patented drugs in Sweden [8] [9] [10] [11] . These included angiotensin receptor blockers versus generic angiotensin-converting enzyme inhibitors (ACEIs), patented statins versus generic statins and duloxetine [8] [9] [10] [11] . Duloxetine was restricted to patients with depression or general anxiety disorders who had been prescribed at least two other antidepressants and not reached their treatment goals [9, 11] . The French reimbursement agency has also evaluated over 4,000 products. This is because products of no real therapeutic value were costing the French health service over €450 million per year before the start of the review [6] . The first wave of the reviews resulted in 72 products being removed from the reimbursement list. A further 282 products were removed in 2006, with more products delisted in recent years [6] . Recent reforms in Germany resulted in the delisting of atorvastatin from the reimbursement list, as there were no outcome data showing superiority over generic simvastatin but it carried a considerably higher price [12] . The Institute of Quality and Efficiency in Health Care, Germany (IQ-WIG) also recommended the delisting of long-acting insulin analogues as there were no outcome data demonstrating superiority over neutral protamine Hagedorn (NPH) insulins to justify the appreciably higher prices in both type I diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) [13] [14] [15] [16] . This led to price reductions of long-acting insulins soon after the initial activities to help maintain reimbursement for these drugs, which have persisted [17] . The findings are similar to those from the Cochrane Review of long-acting insulins, which also found long-acting insulins only have a minor clinical benefit, if at all, versus NPH insulins in patients with T1DM or T2DM [18, 19] . In 2002, the UK National Institute for Health and Care Excellence (NICE) recommended NPH insulins as first-line treatment in patients with T2DM, with long-acting insulins only recommended in specific circumstances, with glargine a potential option for patients with T1DM [14, 20] . The specific circumstances were as follows [20] .
• Those who require assistance from a carer or healthcare professional to administer their insulin injections.
• Those whose lifestyle is significantly restricted by recurrent symptomatic hypoglycaemic episodes.
• Those who would otherwise need twice-daily basal insulin injections in combination with oral antidiabetic drugs.
Similarly, the Pharmaceutical Management Agency (PHARMAC) in New Zealand only approved long-acting insulins for reimbursement as second-line therapy [21] . This includes patients who are allergic to conventional insulins or who have failed to control their diabetes with conventional insulins [21] . In Canada, the Canadian Agency for Drugs and Technologies in Health similarly only recommended long-acting insulins in patients experiencing significant hypoglycaemia with human insulins [14] . This is perhaps not surprising, with a number of published studies showing at best only modest health gains with the long-acting insulins [14, 19, 22, 23] .
The State of Minas Gerais in Brazil has also introduced a number of measures to enhance the quality and efficiency of future prescribing. This includes the instigation of the Commission of Pharmaceuticals and Therapeutics (Comissão de Farmácia e Terapêutica [CFT]) [24] . The Commission has a mandate to recommend the inclusion and exclusion of drugs funded by the State and distributed by the state branch of the public healthcare system (Sistema Ú nico de Saúde [SUS/MG]) [24] . The reviews are based on available scientific evidence of relative efficacy, safety and cost effectiveness versus current standards [24] , mirroring activities in a number of European countries [3, 4, 6, 14, [25] [26] [27] . Consequently, they provide a scientific basis for potential future activities and deliberations by the State authorities. This is because, in Brazil, the government subsidises the list of medicines to be provided to the population. When doctors do not prescribe certain drugs because they are not included in the standard list of publically available drugs, some patients then sue the state to try and obtain them. This is because under Brazilian law, there is a constitutional principle of universality and comprehensiveness [28] . However, this system can be abused as illustrated by 2,412 lawsuits between October 1999 and 2009 [28] , particularly via the private sector, thereby serving the interests of pharmaceutical companies rather than health authorities with their fixed budgets [28] . The belief is that thorough systematic reviews will provide robust arguments to successfully combat future lawsuits.
Insulin analogues were originally developed to improve the safety, efficacy and comfort of treating patients with diabetes mellitus. Such drugs have a chemical structure analogous to that of insulin and are classified as long-acting (glargine and detemir) or fast-acting (lysine-proline [lispro], glulisine and aspart).
Insulin glargine was the first insulin analogue developed. Its use in humans was approved by the European Medicines Agency in 2000, and it was introduced into clinical practice early in the last decade. In Brazil, this drug was registered by the National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária [ANVISA]) in 2003, when it also began to be marketed. The drug was marketed as having an improved reduction in hypoglycaemic episodes and increased comfort for patients, despite limited confirmatory evidence [29] , leading to a rapid uptake.
Initially [30] . Overall, the number of administrative requests has grown since insulin glargine was included in the State List of Medicines, corresponding to 2,632 1 people. At the same time, the expenses of Minas Gerais State Treasury with insulin glargine grew an average of 291 % per year, reaching almost $US6 million in 2011 2 ( Fig. 1 ). In Brazil, the cost of treating a patient with insulin glargine is 536 % that of treatment with NPH insulin [31] .
In addition in 2009, CFT/SUS/MG was informed of the results of studies indicating a higher risk of malignancy in diabetic patients treated with insulin analogues [32, 33] . This, together with concerns surrounding the value of insulin glargine versus NPH insulins, motivated the SES/MG to request the Collaborating Centre for Pharmacoeconomic and Epidemiologic Studies of the Federal University of Minas Gerais, a partner of SES/MG in technical-scientific studies, to perform a systematic review assessing the efficacy and safety of the insulin analogue glargine in patients with T1DM.
Therefore, the objective of this study is to assess the efficacy and safety of insulin glargine compared with NPH insulin in patients with T1DM based on a full systematic review of currently available evidence. This builds on previous reviews [16, 18, 20, 22, 23, 34] . The findings will then be used to evaluate whether insulin glargine should be maintained on the list of the SUS in Minas Gerais, Brazil. Alternatively, the findings may provide published data to support future recommended activities by the State of Minas Gerais. This could include suggesting that the State negotiates price reductions with the manufacturer. In addition, the findings may provide potential arguments to defend against future law suits when these occur in the absence of successful negotiations.
Methods
A systematic review was performed using the software 'Reference Manager' to identify potentially relevant studies published between January 1970 and July 2009 in MEDLINE (PubMed), the Latin American and Caribbean Centre on Health Sciences Information (Literatura LatinoAmericana e do Caribe em Ciências da Saúde [LILACS]), the Cochrane Controlled Trials Databases and the National Health Service (NHS) Centre for Reviews and Dissemination. The studies selected dealt with the efficacy/effectiveness of insulin glargine in the treatment of patients with T1DM and included a survival analysis, the definition of a response and adverse effects.
The following keywords in Portuguese, English and Spanish were used in the search: type 1 diabetes mellitus, glargine insulin, NPH insulin, regular insulin, animal NPH insulin, recombinant NPH insulin, animal regular insulin, recombinant regular insulin, humans, efficacy, effectiveness and cost effectiveness.
An illustration of the search strategy for PubMed is included in the Appendix.
The following analysis criteria were established regarding the inclusion of studies in the review:
1. Intervention: monotherapy with insulin glargine or combined regimens with other insulin formulations. 2. Type of study: randomised controlled clinical trials including comparisons between drugs used in the treatment of patients with T1DM, other insulins or best supportive care (systematic reviews of clinical trials identified during the search were also used in the comparison and discussion of results).
The exclusion criteria included the following:
• studies published in languages other than English, Portuguese and Spanish; • studies not performed in humans;
• those unrelated to T1DM;
• studies lacking at least one of the outcome measures of efficacy and/or safety.
Initially, to verify whether they complied with the inclusion criteria, the titles of all the studies located were assessed. Next, two independent reviewers (AS and RN) also assessed the abstracts. A third reviewer (LD) subsequently analysed studies where there was no inter-reviewer agreement regarding potential inclusion.
The outcome measures considered included the following: blood levels of glycated haemoglobin, episodes of hypoglycaemia, adverse effects and the reduction of microvascular and macrovascular end-organ complications of T1DM.
A modified Jadad scale was used to assess the methodological quality of the randomised controlled clinical trials [35] . The assessment of the quality of the studies was also performed by two independent reviewers (AS and RN), with input from a third reviewer (LD) in cases of disagreement between the two reviewers.
The study was approved by the Research Ethics Committee of the Federal University of Minas Gerais (Ruling No. ETIC 0588.0.203.000-09).
Results

Search Strategy
The initial search strategy identified 803 titles and abstracts (Fig. 2) . Of these 803 studies, 666 were excluded based on their titles. These included nine studies that had not been performed in humans, 108 that were not related to T1DM, 546 that did not describe comparative results of the effectiveness of the investigated drugs and three that did not report on at least one of the considered outcome measures of efficacy/effectiveness (blood level of glycated haemoglobin, measurements of glycaemia, episodes of hypoglycaemia, reduction of microvascular and macrovascular events, adverse effects, survival analysis). The abstracts of the remaining 137 studies were subsequently analysed. Of these, 6, 4, 64 and 5 (for a total of 79), respectively, were excluded for the same reasons mentioned above (Fig. 2) .
A total of 58 studies remained for complete review, 50 of which were classified as studies on effectiveness based on observational data. Consequently, these were excluded under our inclusion criteria. As a result, only eight papers using formal clinical trials were selected for analysis. One of these could not be retrieved and so was excluded. However, one additional study was subsequently found and selected following a manual search, making a total of eight studies for the systematic review ( Table 1) .
The eight clinical trials scored an average of 2.125 points on the methodological assessment scale. According to Table 1 , no study had a score of 5 or 6, which represents high quality/low risk of bias. Three studies had scores of 3 or 4, which indicate appropriate quality/moderate risk of bias and five studies had a score of 0-2, denoting poor quality/high risk of bias. According to the Jadad criteria, the main limitations identified were data collectors or evaluators were not blinded (eight studies); inappropriate randomisation method (five studies); lack of intention-totreat (ITT) analysis (three studies with a further one where a full ITT analysis was not performed) and failure to describe the excluded participants or dropouts (one study) ( Table 1 ). All of the eight clinical trial studies were open label and investigated the use of insulin glargine administered once per day. The lack of blinding was justified by the authors by the different physical appearances of different insulin formulations. In the study by White et al. [36] , the assessment of the results was blinded, and in the studies by Rosenstock et al. [37] and Pieber et al. [38] , which compared two different concentrations of insulin glargine with another insulin formulation, the comparison between the different concentrations of insulin glargine was blinded. All of the studies were described as randomised; three among them (Doyle et al. [39] , Raskin et al. [40] and Chatterjee et al. [41] ) mentioned the method used for randomisation. An ITT analysis was described in five studies; however, in one (Schober et al. [42] ), the analysis was not performed on the full ITT population and thus was rated as inappropriate. As a result, this study was downgraded on its modified Jadad score (Table 1) .
Characteristics of the Eight Clinical Trials
Seven studies compared the efficacy of insulin glargine with that of NPH insulin, and Doyle et al. [39] compared the efficacy of insulin glargine to the continuous subcutaneous insulin infusion (CSII) of the analogue aspart. None of the selected clinical trials compared the two available long-action analogues (insulin glargine and detemir). The median number of participants included was 168 (range 32-619), and the duration of follow-up varied between 1 month [37, 38] and 2 years [41] , with a median of 4 months ( Table 2) .
With respect to the loss of participants during the study, Pieber et al. [38] did not mention how many patients completed the study. In the study by White et al. [36] , 23.4 % of participants were lost, and in the remainder of studies, the loss was \12 % (Table 2 ).
Characteristics of Participants and Interventions in the Eight Clinical Trials
The minimum age of included participants was 5 years, and the maximum age was 80 years. Of the 1,591 investigated participants, 56.76 % were female and 43.24 % were male. Pieber et al. [38] and Schober et al. [42] did not distinguish between different ethnic groups; in the remainder of studies, most participants were Caucasian ( Table 2) . The selected studies compared insulin glargine prescribed once per day, NPH insulin administered once or twice daily as a basal treatment and the ultrafast-acting analogues lispro and aspart given in multiple injections or subcutaneous infusion as prandial components. Pieber et al. [38] and Schober et al. [42] used human regular insulin as a prandial component (Table 2) . The following reasons were given for censoring in the studies: lost to follow-up, hypoglycaemia, adverse reaction to aspart, dehydration, pancreatic cancer (unrelated to treatment), lack of a baseline assessment of glycated haemoglobin (HbA 1c ), adverse events, problems related to monitoring mechanisms, automatic glycaemia (continuous glucose monitoring system [CGMS] ) and withdrawal of consent.
Associated comorbidities were investigated but were not discussed in the selected studies.
Outcome Measures
The efficacy of analogous glargine was assessed in all of the eight clinical studies (Table 3) . White et al. [36] did not find any statistically significant difference between insulin glargine and NPH insulin in terms of glycaemia measured by means of continuous automatic monitoring. Fasting glycaemia was significantly improved with insulin glargine in Rosenstock et al. [37] : 81 mmol/L with insulin glargine (30 lg/mL zinc), 86 mmol/L with insulin glargine (80 lg/ mL zinc) and 87 mmol/L with NPH (p \ 0.001); and in Schober et al. [42] : a 1.29 mmol/L reduction in the insulin glargine group versus 0.68 in the NPH group (p = 0.02). Raskin et al. [40] also documented the advantages of using insulin glargine over NPH in terms of the plasma and blood levels of fasting glucose, as assessed at baseline, at the time of any outcomes and every week. However, the frequency of nocturnal hypoglycaemia was lower in users of NPH insulin than in those using glargine (p = 0.06).
Pieber et al. [38] found a significant difference (p = 0.030) in the overall comparison of HbA 1c values in patients using insulin glargine (30 lg/mL zinc and 80 lg/ mL zinc), with 7.71 and 7.77 %, respectively, compared with 7.88 % with NPH. Chatterjee et al. [41] documented an HbA 1c outcome value of 8.07 % in users of insulin glargine and 8.26 % in users of NPH (p = 0.04). With regard to the fasting plasma glucose level, the average values were 8.42 mmol/L in insulin glargine users and 11.42 mmol/L in NPH insulin users (p = 0.01).
Only one 16-week study [39] directly compared insulin glargine and aspart. The average HbA 1c levels were 8.2 ± 1.1 % in the glargine group and 8.1 ± 1.2 % in the aspart CSII group (p \ 0.05). The number of patients who attained HbA 1c levels B7 % in the 16 weeks were two (12.5 %) and eight (50 %) (p \ 0.05), respectively.
The literature mentions a reduction in the episodes of hypoglycaemia as a possible advantage of insulin glargine. When White et al. [36] analysed this, they found a significant difference in the adjusted average glucose levels in the insulin glargine group, at \50 mg/dL (\2.78 mmol/L; p = 0.0198) and \40 mg/dL (\2.22 mmol/L; p = 0.0130) compared with the NPH/slow-acting insulin group (p = 0.0298). However this did not translate into a statistically significant reduction in the incidence of hypoglycaemia. However, Pieber et al. [38] showed insulin glargine significantly reduced the incidence of hypoglycaemia when compared with NPH insulin. Chase et al. [43] also proved the superiority of insulin glargine when they assessed the incidence of hypoglycaemia between 50 mg/ dL and 70 mg/dL. However, Rosenstock et al. [37] observed a significant difference favouring NPH insulin despite insulin glargine improving fasting glycaemia. All the patients in the HOE 901 glargine (80 lg/mL zinc) group, 97.5 % of patients in the HOE 901 (30 lg/mL zinc) group and 93.2 % of those in the NPH group experienced at least one episode of hypoglycaemia (p = 0.030). The remainder of studies did not report any statistically significant results. In the study by Doyle et al. [39] , four patients in the glargine group experienced one episode of severe hypoglycaemia, and one patient in the continuous subcutaneous aspart infusion group developed nocturnal hypoglycaemia. However, these findings were not statistically significant.
In the study by White et al. [36] , 17.6 % of patients using insulin glargine and 8.9 % of those using NPH/slowacting insulin required treatment for severe adverse events. In this same study, the average time to hypoglycaemia in week 24 was statistically shorter in the insulin glargine group. In the study by Chase et al. [43] , 15 (17.6 %) patients using insulin glargine and eight (8.9 %) patients in the NPH/slow-acting insulin group reported adverse reactions; however, this difference did not reach statistical significance. In terms of the incidence of severe adverse events, the frequency was higher in the insulin glargine group (p \ 0.05) in this study.
Injection site reactions were described by four studies. Rosenstock et al. [37] and Pieber et al. [38] did not specify which group. In Raskin et al. [40] , pain was more common with insulin glargine (6.1 %) than NPH insulin (0.3 %); however, haemorrhage was more common with NPH insulin at 4.2 versus 3.2 % with insulin glargine. In Schober et al. [42] , injection site reactions occurred in 9.2 % of patients receiving insulin glargine and 8.6 % of patients with NPH insulin. Doyle et al. [39] found that ketoacidosis occurred in one patient using insulin glargine; Schober et al. [42] found that it occurred in one patient in the insulin glargine group (0.6 %) and four patients (2.9 %) in the NPH insulin group.
The body mass index (BMI) at baseline of the participants of all investigated studies varied between 18.8 and 25.7 and did not exhibit any significant alteration in the studies that assessed this variable during follow-up, namely, Chase et al. [43] , Doyle et al. [39] and Chatterjee et al. [41] .
The following diabetes complications were investigated but were not addressed by any of the analysed studies: neuropathy, nephropathy, retinopathy, heart disease, effect on the brain vessels, neoplasias and hospitalisations. Consequently, no comment could be made in our systematic review.
Discussion
This systematic review analysed the glycaemic control, as well as the frequency and severity of episodes of hypoglycaemia, that were associated with the treatment of patients with T1DM with either insulin glargine or NPH insulins. Although the analysis of isolated results indicated clinical benefits from insulin glargine in patients with T1DM in terms of a reduction of fasting glycaemia, insulin glargine did not show any advantages when this parameter was analysed together with a reduction of the frequency of episodes of hypoglycaemia with the control of glycaemia assessed by means of HbA 1c , apart from one study (Table 3) . These results are consistent with the findings from the systematic review performed by the IQWIG [13, 16, 19] , the review by the Cochrane collaboration as well as other recent reviews [14, [18] [19] [20] [21] . These various reviews have resulted in a number of health authorities across continents either delisting long-acting insulins or relegating them to second-line use [13-16, 19-21, 44, 45] . For instance, in Scotland, the authorities recommend that insulin glargine should only be used in patients with T1DM who are ''at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins'' [44] . Demand side measures routinely used in Scotland to enhance adherence to this guidance include academic detailing, monitoring of physician prescribing and financial incentives [1, 2, 46] . In the studies by Pieber et al. [38] and Chatterjee et al. [41] , insulin glargine significantly reduced HbA 1c levels compared with NPH insulin. However, due to the number of episodes of nocturnal hypoglycaemia, only the first study demonstrated an advantage in the use of insulin glargine (Table 3) .
Frequent episodes of nocturnal hypoglycaemia are also mentioned as an argument to justify the preferential use of analogues compared with other insulin formulations. However, among the studies that analysed this variable, only three reported statistically significant results (Table 3) . Raskin et al. [40] obtained results favourable to NPH (p = 0.06) but this was not statistically significant. Pieber et al. [38] obtained results favourable to glargine and Chase et al. [43] proved the superiority of insulin glargine when they assessed the incidence of hypoglycaemia between 50 mg/dL and 70 mg/dL. Doyle et al. [39] reported improved results using continuous aspart infusion compared with glargine in the reduction of HbA 1c on the 16th week of treatment. However, this study only included 32 patients (Table 2) .
Singh et al. [22] performed a meta-analysis that focused on the efficacy and safety of insulin analogues in the treatment of patients with T1DM, T2DM and gestational diabetes. These researchers concluded that the fast-and slow-acting analogues exhibited little additional benefit over conventional insulin formulations in terms of the control of glycaemia or the reduction of episodes of hypoglycaemia. These authors further observed that higher-quality studies with longer durations of follow-up are needed to establish whether the insulin analogues are able to reduce the risk of chronic complications of diabetes mellitus. Based on this study, the World Health Organization requested an updated review to be assessed at the 18th Expert Committee on the Selection and Use of Essential Medicines. This review concluded that the differences between long-acting insulin analogues and human insulin formulations are notably small. There was no clear clinical advantage from the use of long-acting insulin analogues compared with human insulin, and the advantages found were inconsistent in terms of their statistical and clinical significance. In addition, the long-acting insulin analogues did not prove to be consistently cost effective, and there is uncertainty as to their association with an increased risk for cancer. This review further emphasised the high risk of bias of the studies assessing long-acting insulin analogues, due to their low quality and the fact that many of the researchers in the studies had links to the pharmaceutical industry [47] . Consequently, the findings from this review substantiates the findings from our systematic review.
Several other meta-analyses have reached similar conclusions [18] [19] [20] 23] . This supports the recent recommendation by the Brazilian Network for Health Technology Assessment stating that resources ought to be employed in programmes seeking to maximise the treatments available in the public healthcare network, as the current evidence does not support the superiority of long-acting insulin analogues [31] .
A further issue concerning patients on insulin therapy is weight gain, which is a frequent finding. The present review was not able to reach any robust conclusions concerning alterations of the BMI based on the selected studies.
Several studies discussed the mitogenic potential of insulin analogues. Glargine exhibits a 6.5-fold greater affinity for the insulin-like growth factor (IGF)-1 receptor than does human insulin and an eightfold greater potential to stimulate the synthesis of DNA by human osteosarcoma cells [48] . Hemkens et al. [32] found a higher incidence of cancer than expected in patients using glargine compared with human insulin. A study performed in Sweden in 2009 found a greater incidence of breast cancer in women using insulin glargine in monotherapy than in those using other insulin formulations, although the conclusion was not definitive [33] . Conversely, Currie et al. [49] did not find any association between the use of insulin analogues and an increased risk of cancer compared with human insulin. Smith and Gale [50] observed that, although the evidence is insufficient for conclusions, this possibility must be subjected to surveillance, and more prospective studies in this area are needed.
A further preoccupation derived from the increased affinity for the IGF-1 receptor is the possibility of a faster evolution of retinopathy, perhaps up to threefold higher in patients using insulin glargine than in those taking human insulin. Nevertheless, an analysis requested by the US FDA dispelled this concern, as reported by Smith and Gale [50] .
Despite the concern with the chronic complications of diabetes and the mitogenic effects attributed to insulin analogues, none of the analysed studies investigated their influence on such conditions. The systematic review performed by Plank et al. [34] observed that other possible long-term undesirable effects have also not yet been studied. We acknowledge that we have not fully discussed the safety of long-acting insulins. However, the length of the clinical trials did not allow us to fully review these.
Consequently, we are unable to comment further on the long-term safety of insulin glargine.
Given the increased use of insulin analogues in young females with T1DM, the safety profile of such drugs in pregnancy is of paramount importance. However, none of the analysed studies included insulin-dependent pregnant women.
Despite the findings from the various reviews and health authority deliberations [14, 16, 18-20, 23, 44, 45, 47] , there is growing use of long-acting insulins across countries and in this Brazilian state [14, 20, 45, 51] . This is despite the appreciably increased costs of insulin glargine versus NPH insulins. Potential reasons for the continued growth in their sales include marketing activities by pharmaceutical companies targeting healthcare providers; attractive devices for the administration of long-acting insulin analogues that facilitate application and entice patients; removal of less expensive insulin formulations from the market; and reduced weight gain [29] . In their review, Cohen and Carter [29] discussed the relationship between the increased use of long-acting insulins and the lack of evidence of increased effectiveness and improved safety of insulin glargine and NPH insulins.
From a methodological perspective, the assessed studies scored low, primarily between 0 and 2, which denotes poor methodological quality/high risk of bias. All studies were open-label, which are admittedly more prone to methodological bias.
Such methodological difficulties were justified by the authors, as the macroscopic physical differences among insulin formulations make blinding impossible with regard to both experimental subjects and investigators. However, blinding is recommended, at least when assessing the results or in the titration of doses, which is rarely mentioned as having been performed in actual practice, as the method used for randomisation was not described.
In addition, Gill et al. [51] observed that the cost-benefit ratio of insulin glargine does not support its use, particularly in low-income countries, although it might be indicated in specific conditions when there are sufficient resources.
Although studies reporting economic assessments were not the subject of this present systematic review, given the higher monthly cost and the lack of clear therapeutic advantages of insulin glargine compared with NPH insulin, the cost-effectiveness ratio seems to favour the use of the latter. For this reason, the manufacturer of insulin glargine should present SUS managers with justifications for the higher cost of this drug, including any new evidence as well as more accurate assessments of its cost effectiveness and impact on quality-adjusted life-years (QALYs) versus NPH insulins. Alternatively, price reductions should be sought to address concerns surrounding the value of insulin glargine versus NPH insulins. This is because a recent UK study estimated potential savings of up to £625 million over the decade with greater use of NPH insulins versus long-acting insulins [14] . The savings would have been higher with a greater differential between the cost of the various insulins, e.g. insulin glargine in the UK is less than double the cost of NPH insulin [14] , appreciably lower than the 536 % differential seen in Minas Gerais. If price reductions are not achieved, the authorities in Minas Gerais should seek to delist insulin glargine from the state list of medicines. Both activities are in line with those already undertaken by authorities in Germany. The alternative is to restrict the funding and use of long-acting insulins to second line, which is similar to the current situation in the UK [14, 20, 44] . However, this requires robust systems of physician monitoring and incentives to make sure the objectives of such initiatives are met; otherwise there will be disappointment [1, 2, [52] [53] [54] . Consequently, we believe the authorities should, in the first instance, seek price reductions from the manufacturers of insulin glargine to help the sustainability of the healthcare system in Minas Gerais. This can be through discounts, rebates or pricevolume agreements, which is similar to activities in other countries [2, 6, 26, [55] [56] [57] [58] .
We believe the findings of our systematic review, and its subsequent publication and ensuing debate, will help the authorities in Minas Gerais achieve their aims. If there is delisting due to the reluctance by the manufacturers to appreciably lower the price of insulin glargine, we believe this review will provide the judiciary with robust arguments and reasons to reduce the number of successful litigation cases brought by patients, which have been facilitated by pharmaceutical companies.
We acknowledge that our systematic review only went up to July 2009. However, we do not believe any more recent randomised controlled trials, if they have been performed and published, will have altered our conclusions given the number of existing papers demonstrating no statistically significant advantage for insulin glargine for reducing both hypoglycaemia episodes and HbA 1c levels (Table 3) .
Conclusions
The present systematic review could not find any overall clinical benefits with insulin glargine compared with other investigated insulin formulations when glycaemic control and the frequency and severity of episodes of hypoglycaemia were analysed together. For these reasons, the SUS state managers are advised to delist insulin glargine, or, alternatively, to negotiate a price reduction with the manufacturer to enhance its value. Publication of this systematic review provides support for this decision as well as support to combat potential law suits if discussions are not satisfactory. 
